Broose Wellness Tirzepatide Review: Package Totals & Microdosing Limits

Broose Wellness offers injectable tirzepatide with consultation and ongoing provider support. Its four-week option is $339. Longer packages may reduce the equivalent periodic cost, but the amount paid upfront and the refund boundaries matter more than a smaller divided number.¹

Broose’s shorter purchase can be a useful starting comparison. Longer packages deserve a written refund explanation before the savings justify tying up more money.

What the advertised price buys

The October 7 direct pricing showed $339 for four weeks, $939 for 12 weeks, $1,739 for 24 weeks and $3,499 for 52 weeks. These are package totals. Longer-plan prices were not consistently confirmed in current public pricing, so obtain a written quote before relying on these dated totals.¹

How the care arrangement works

A separate microdosing offering appears alongside standard injectable treatment. It should be discussed as a different proposed regimen. A lower price or smaller dose does not demonstrate the same clinical effects as an approved tirzepatide regimen, and a patient should not select their own dosing schedule from marketing categories.¹

Pharmacy, eligibility and payment terms

The product page does not identify the dispensing pharmacy, and the sources do not establish state eligibility or dependable cancellation and refund rules. Complete current refund terms were not publicly confirmed for this review.²

How much do the longer Broose packages save?

At the listed four-week price, three consecutive four-week purchases would total $1,017. The October 7 twelve-week package at $939 is $78 less for the same stated duration. That comparison is more informative than putting a twelve-week total beside a calendar-month equivalent. The saving may matter, but so does losing flexibility if the treatment is unsuitable or the service is hard to reach. Before paying for 24 or 52 weeks, obtain a written explanation of unused-treatment refunds, shipment timing and what happens if your prescribed dose changes. The public placeholder prices make this written confirmation especially important.

Readers weighing a longer Broose package can compare LovelyMeds for plan-length pricing and Rese Wellness for an upfront initial package followed by manual reordering. Check unused-treatment refunds before deciding that a lower periodic equivalent is worth a larger first payment.

When comparing Broose packages, distinguish the prescribed regimen from a price calculation. Read about tirzepatide dosing, compounded medication and approved Zepbound costs before treating the smallest equivalent as the best fit.

Compounded products are not FDA-approved. FDA advises using them only when an individual patient’s medical needs cannot be met by an approved drug.³

Comparing the 24- and 52-week totals

At $339 for four weeks, six separate four-week purchases would total $2,034 over 24 weeks. The October 7 package total of $1,739 would save $295 for that stated duration. Thirteen four-week purchases would total $4,407 over 52 weeks, compared with the listed $3,499 package total, a $908 difference. These are arithmetic comparisons of the recorded prices, not confirmation of today’s checkout or a guarantee of continuing clinical eligibility.

The larger saving also comes with a longer commitment. Ask whether the package is paid in full, whether medication is sent at once or in stages and whether future clinical reviews remain included throughout. A shipment schedule alone does not answer whether unused funds can be recovered.

When the shorter option may be more useful

The four-week option provides a clearer starting comparison for someone new to the service. It may cost more over time, but avoids choosing a half-year or year-long package before the patient understands the communication and refill arrangements. This tradeoff should be explicit rather than hidden inside a monthly-equivalent advertisement.

The separate microdose service also calls for a separate clinical discussion. Ask which regimen the quoted package actually covers and whether changing between programs changes the financial terms. A marketing category should not become a patient-selected dosing decision or a reason to assume the cheapest package is clinically comparable.